Description
Sermorelin is a synthetic 28-amino acid peptide analog of growth hormone-releasing hormone (GHRH). Sermorelin exhibits immunomodulatory and pro-angiogenic activities. In vivo, sermorelin stimulates secretion of growth hormone from the pituitary gland; it also increases IGF-1 secretion and increases the number of activated immune cells in circulation. Sermorelin induces histamine release from mast cells in a Ca2+-dependent manner. Additionally, this peptide increases secretion of VEGF and chromogranin A, increasing proliferation in neuroendocrine tumor cells.
References
Stepień T, Sacewicz M, Lawnicka H, et al. Stimulatory effect of growth hormone-releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro. Neuropeptides. 2009 Oct;43(5):397-400. PMID: 19747727.
Khorram O, Yeung M, Vu L, et al. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women. J Clin Endocrinol Metab. 1997 Nov;82(11):3590-6. PMID: 9360512.
Estévez MD, Alfonso A, Vieytes MR, et al. Study of the activation mechanism of human GRF(1-29)NH2 on rat mast cell histamine release. Inflamm Res. 1995 Feb;44(2):87-91. PMID: 7544679.
Sato M, Chihara K, Kita T, et al. Physiological role of somatostatin-mediated autofeedback regulation for growth hormone: importance of growth hormone in triggering somatostatin release during a trough period of pulsatile growth hormone release in conscious male rats. Neuroendocrinology. 1989 Aug;50(2):139-51. PMID: 2571099.
